AIM ImmunoTech is trading 6.21% up at $0.25, apparently amid residual biotech momentum following positive Moderna cancer-vaccine news.
- No newly identified company-specific announcement emerged on August 20, 2026.
- The latest substantial update, on August 10, covered second-quarter results and progress in the Ampligen pancreatic-cancer program.
- Broader biotech and major U.S. indexes are weaker, leaving the immediate catalyst uncertain.